ADMA Biologics Reports Q3 2026 Results

What Happened
ADMA Biologics, Inc. announced its financial results and provided a business update for the three months ended June 30, 2026. The company issued a press release dated August 5, 2026, which was furnished with the Form 8‑K (Item 2.02) and is attached as Exhibit 99.1 and incorporated by reference in the filing.

Key Details

• Filing date: August 5, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: three months ended June 30, 2026 (quarterly results / earnings period).
• Press release: furnished as Exhibit 99.1; interactive Inline XBRL cover page data included as Exhibit 104.
• The 8‑K contains the press release and business update; no executive departures or corporate transactions (e.g., mergers/acquisitions) were reported in this filing.

Why It Matters
This filing formally notifies investors that ADMA has released its latest quarterly earnings and business update—key information for assessing recent revenue, profitability, cash position, and operational progress. Retail investors should read the attached press release for the specific financial figures (revenue, net income/loss, guidance, and any operational highlights) and watch for any follow-up filings (10‑Q or management commentary) for fuller details.